Lixisenatide is a GLP-1 receptor agonist that had a brief run as an FDA-approved diabetes drug before being discontinued from the U.S. market, a story that illustrates how fast this drug class has moved rather than any particular failure of the drug itself.
What It Is
Lixisenatide, like exenatide, is a synthetic peptide derived from exendin-4, a compound first identified in Gila monster saliva and later developed into a class of GLP-1 receptor agonist drugs. Sanofi developed and marketed it under the brand name Adlyxin in the United States (it was sold as Lyxumia in other markets). It's a short-acting GLP-1 drug, meaning it clears from the body relatively quickly, and it was designed to be injected once daily, specifically to blunt the blood sugar spike that follows meals, rather than providing the steadier, longer-acting effect of once-weekly drugs like semaglutide or dulaglutide.
Regulatory Status
The FDA approved lixisenatide (Adlyxin) for type 2 diabetes in July 2016. A combination product pairing lixisenatide with insulin glargine, sold as Soliqua 100/33, received FDA approval later that same year. Lixisenatide was never approved for weight management in the U.S., only for type 2 diabetes.
What the Research Showed
Lixisenatide's dedicated cardiovascular outcomes trial, ELIXA, studied the drug in people with type 2 diabetes who had a recent history of acute coronary events, a high-risk population. The trial found lixisenatide was cardiovascularly safe, it didn't increase the rate of heart attack, stroke, or cardiovascular death compared to placebo, but it also didn't demonstrate a cardiovascular benefit the way later trials of other GLP-1 drugs would for their respective drugs. On blood sugar control, lixisenatide produced a comparatively modest effect, roughly a half-percentage-point reduction in A1C versus placebo, smaller than what once-weekly GLP-1 drugs would later demonstrate.
Why It Was Discontinued
Sanofi's decision to pull Adlyxin from the U.S. market reflected commercial reality rather than a safety problem. By the time once-weekly drugs like semaglutide and dulaglutide were established, a once-daily injectable with a smaller A1C benefit and no demonstrated cardiovascular advantage had a hard time competing, even though its safety profile was never in question. Patients and prescribers increasingly preferred once-weekly dosing, and newer drugs in the same broad class offered larger effect sizes on both blood sugar and, eventually, weight.
What This Means If You've Seen It Prescribed
Because lixisenatide and Soliqua were on the market for years, some patients may still encounter the name in older medical records or from international sources, since the drug remains available in some other countries. Anyone currently prescribed it, or considering a switch away from it, should discuss alternatives with their physician rather than stopping a prescribed diabetes medication on their own, since abruptly stopping any glucose-lowering therapy without a medical plan to replace it can affect blood sugar control.
The Bottom Line
Lixisenatide's story isn't one of a failed or dangerous drug; it's an example of how quickly the GLP-1 drug class has advanced. A drug that was a legitimate, FDA-approved treatment option in 2016 became commercially obsolete within less than a decade, not because it stopped working, but because the rest of the field moved to once-weekly dosing with stronger effects.